Palvella Therapeutics Inc. (NASDAQ: PVLA) announced new data from its Phase 2 TOIVA trial showing that all patients with baseline ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE